Cellular senescence mediates fibrotic pulmonary disease
Open accessThe DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index; 18 of the 31 sources its claims cite were checked for support.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by interstitial remodelling, leading to compromised lung function. Cellular senescence markers are detectable within IPF lung tissue and senescent cell deletion rejuvenates pulmonary health in aged mice. Whether and how senescent cells regulate IPF or if their removal may be an efficacious intervention strategy is unknown. Here we demonstrate elevated abundance of senescence biomarkers in IPF lung, with p16 expression increasing with disease severity. We show that the secretome of senescent fibroblasts, which are selectively killed by a senolytic cocktail, dasatinib plus quercetin (DQ), is fibrogenic. Leveraging the bleomycin-injury IPF model, we demonstrate that early-intervention suicide-gene-mediated senescent cell ablation improves pulmonary function and physical health, although lung fibrosis is visibly unaltered. DQ treatment replicates benefits of transgenic clearance. Thus, our findings establish that fibrotic lung disease is mediated, in part, by senescent cells, which can be targeted to improve health and function.
Overview
CoChat Summary
## TL;DR
This study links cellular senescence to idiopathic pulmonary fibrosis (IPF) by showing that senescence markers rise with disease severity in human lung tissue and that senescent fibroblast secretions are profibrotic. In a bleomycin mouse model, clearing senescent cells improved lung function and physical health, and dasatinib plus quercetin (DQ) reproduced the benefits of transgenic senescent-cell ablation.
## Key findings
- In human IPF lung samples, CDKN2A (p16) was significantly upregulated and increased with disease severity; higher pulmonary p16 expression correlated with reduced FVC, diffusion capacity, and SF-12 physical component score.
- In IPF tissue, p16-positive epithelial cells and fibroblasts were found in fibroblastic foci and honeycomb lung, and TAF-positive cells / γH2A.X foci were significantly increased relative to controls.
- In the bleomycin mouse model, lung injury increased whole-lung p16 expression by threefold, and SASP-related transcripts including Mcp1, Il6, Mmp12, Col1a1, and Tgfβ rose after bleomycin exposure.
- Senescent fibroblast conditioned medium was fibrogenic in vitro: it increased αSMA positivity to 62% vs 21% with control conditioned medium, increased traction forces, and induced fibrosis genes such as ACTA2, COL1A1, COL1A2, and FN1.
- In mice, senescent-cell clearance improved pulmonary/physical outcomes: Penh rose about twofold after bleomycin and was diminished by AP or DQ; lung compliance fell by 40% in vehicle-treated bleomycin mice but only 15% with AP or DQ; body weight loss averaged 3.6 g with vehicle vs about 1.6 g with AP/DQ; treadmill distance to exhaustion was >37% further with AP/DQ than vehicle.
- The paper states that histological fibrosis reductions did not reach statistical significance, despite functional benefits.
## Methods
- Human data came from LTRC control and IPF lung tissue samples, including microarray and RNA-seq datasets; the paper reports IPF n=27 and control n=10 for p16 immunohistochemistry, and transcriptome analyses stratified by FVC severity.
- The mouse study used male Ink-Attac mice given aerosolized intratracheal bleomycin (2 U/kg) or PBS, then randomized to AP20187, dasatinib plus quercetin (DQ), or vehicle at either an early prevention timepoint or a later treatment timepoint.
- Analyses included FACS of lung fibroblasts, epithelial cells, and endothelial cells, immunohistochemistry / immunofluorescence, conditioned-medium assays in IMR90 fibroblasts, traction force microscopy, RT-PCR, and statistical modeling with regression and multiple-comparison correction.
## Limitations
- The paper states that the bleomycin model spontaneously resolves, with resolution varying by factors such as genetic background and microbiome, which limits interpretation of late-stage effects.
- The authors state that they could not disentangle senescence-dependent from senescence-independent events governing fibrosis resolution.
- Lung fibrosis histology did not improve significantly after senescent-cell clearance, despite functional gains; the paper itself notes this may reflect the short time course and heterogeneity of the bleomycin model.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
13 Valid · 0 Not valid · 8 Not checked · 94 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Through secretion of the senescence-associated secretory phenotype (SASP), a broad repertoire of cytokines, chemokines, matrix remodelling proteases and growth factors, senescent cells paracrinely promote proliferation and tissue deterioration8.”
§ Cellular senescence mediates fibrotic pulmonary disease > Abstract
What the sources say
- Partly supportedcites [8] van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446 (2014). sourceExperimental — accuracy not yet measured
In “Senescence is a multi-step evolving process” (page unavailable), the paper says SASP-mediated paracrine signalling affects cell proliferation. In “Senescence in ageing and age-related disease” (page unavailable), it says SASP components are thought to promote proliferation of neoplastic cells and may intensify age-related tissue deterioration. The citing sentence presents those qualified effects as established and general. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Cellular senescence is an evolutionarily conserved state of stable replicative arrest induced by pro-ageing stressors also implicated in IPF pathogenesis, including telomere attrition, oxidative stress, DNA damage and proteome instability.”
§ Cellular senescence mediates fibrotic pulmonary disease > Abstract
What the sources say
- Partly supportedcites [8] van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446 (2014). sourceExperimental — accuracy not yet measured
The Abstract and 'Senescence is a multi-step evolving process' describe growth arrest, including a transition to stable cell-cycle arrest. 'Causes and effector pathways of senescence' identifies telomere erosion, DNA lesions, reactive oxygen species and proteotoxic stress as senescence-related stressors. The cited passages do not establish that senescence is evolutionarily conserved or that these stressors are implicated in IPF pathogenesis; the paper also distinguishes replicative senescence from other forms of senescence. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Critically, impaired capacity to resolve fibrotic bleomycin injury has been associated with accumulation of apoptosis-resistant, senescent myofibroblasts3.”
§ Cellular senescence mediates fibrotic pulmonary disease > Results > Senescent cell retention impairs fibrosis resolution Taken together, our in vivo results strongly support the hypothesis that elimination of senescent cells improves fibrotic pulmonary disease when treatment is initiated at the onset of pathogenesis. We next sought to test the clinically important question of whether senescent cell clearance provides comparable benefit when initiated at a timepoint when pathology has fully developed. Ink-Attac mice contained a strong senescent signature in lung fibroblasts and epithelial cells 2 weeks post-bleomycin challenge (Fig. 2), a timepoint of well-established fibrotic remodelling in the lung15. Accordingly, we administered a single dose of bleomycin or PBS through aerosolized intratracheal administration to Ink-Attac mice. Two weeks post challenge, we randomized bleomycin-exposed mice to AP, DQ or vehicle treatment groups based on change in body weight and non-invasively measured airway resistance (Penh). Mice were treated for 2 weeks and were killed 4 weeks following bleomycin or PBS exposure (Fig. 5a). Body weight monitoring revealed that, similar to our previous experiments (Fig. 4f), mice that received bleomycin lost substantial body mass, relative to mice that received PBS. Upon treatment initiation on day 14, mean body weight of mice treated with AP plateaued, while vehicle-treated, bleomycin-exposed counterparts continued to lose weight (Fig. 5a), suggestive of physical benefit afforded by senescent cell clearance, even when treatment is initiated in later-stage disease. Spontaneous resolution is an inherent limitation of the bleomycin IPF model, with the rate and variability of bleomycin-induced pathology resolution dependent on complex factors, including genetic background and the microbiome3839. Indeed, both endpoint compliance (Supplementary Fig. 6) and comparison of Penh airway resistance at endpoint (4 weeks post challenge) to measures taken at the treatment randomization timepoint (2 weeks post challenge) revealed appreciable, albeit variable, improvement in all bleomycin-exposed groups, including vehicle-treated mice, with AP-treated mice showing greatest improvement (Fig. 5b). Thus, in our hands, the 3–4-week-period following a single bleomycin exposure represents a pivotal window of natural resolution (Figs 4 and 5a,b). Critically, impaired capacity to resolve fibrotic bleomycin injury has been associated with accumulation of apoptosis-resistant, senescent myofibroblasts3. As we were unable to disentangle senescence-dependent and -independent events governing resolution, we queried whether p16 expression, a measure of senescent burden, was associated with indicators of disease persistence. Impaired lung function, as measured by endpoint airway resistance (Penh) (Fig. 5c) and airway compliance (Fig. 5d), correlated significantly with p16 transcript abundance. This finding is consistent with associations drawn in humans, in which increased p16 expression correlated significantly with reduced FVC, pulmonary diffusion capacity and physical function (Supplementary Fig. 1). Similarly, in bleomycin-exposed mice, expression of the inflammatory and fibrogenic SASP factors Mcp1 (Fig. 5e), Pai1 (Fig. 5f), Mmp10 (Fig. 5g) and Col1a1 (Fig. 5h) robustly correlated with p16 transcriptional activation. These results further support the notion that the presence and activities of senescent cells may dictate resolution capacity following bleomycin-induced pathology.
What the sources say
- Supportedcites [3] Hecker, L. et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci. Transl. Med. 6, 231ra247 (2014). source
The Introduction states that aged mice have impaired fibrosis resolution associated with senescent, apoptosis-resistant myofibroblasts. The Results identify bleomycin as the lung-injury model and report accumulation of senescent myofibroblasts in aged mice with persistent fibrosis. Page numbers are not provided in our copy. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescence was confirmed by expression profiling (p16, SASP factors) and/or SA-β-gal staining32 21 days post radiation.”
§ Cellular senescence mediates fibrotic pulmonary disease > Methods > Cell culture For experiments employing radiation-induced senescence, IMR90 (passages 5–7; ATCC, catalogue number CCL-186) and primary human fibroblasts (passages 3–6) were exposed to 10 Gy radiation or sham conditions using a RS2000 X-Ray Irradiator (RAD Source Technologies, Suwanee, GA). Normal bronchial epithelial cells (passages 4–7, Lot 7F3000, Lonza, Walkersville, MD) were exposed to 5 Gy or sham conditions. Senescence was confirmed by expression profiling (p16, SASP factors) and/or SA-β-gal staining32 21 days post radiation. For SA-β-gal staining, cells were fixed for 10 min in 2% formaldehyde+0.2% glutaraldehyde in PBS at room temperature. Cells were rinsed with PBS and incubated overnight in SA-β-gal staining solution containing the following: 1 mg ml−1 X-gal, 40 mM citric acid/sodium phosphate buffer pH 6.0, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM sodium chloride and 2 mM magnesium chloride in water. Cells were then rinsed in PBS and stored at 4 °C until imaging. Media applied 20 days post irradiation (or sham) was collected 24 h later and was diluted with NCM to reflect equivalent source cell concentrations. ProcartaPlex immunoassays (Affymetrix eBioscience) were used for CM secretome composition assessment, according to the manufacturer's specifications. Non-irradiated IMR90 cells (passages 5–7) were treated with NCM, NCM+2 ng ml−1 TGFβ, CCM or SASP-CM and applied to downstream analyses as indicated. Primary human fibroblasts collected from human patients were authenticated through αSMA staining. For senolytic treatment, sham and irradiated primary human fibroblasts were treated with indicated concentrations of DQ or navitoclax for 3 days, starting at day 20 post irradiation or sham exposure. Cell viability after drug treatment was measured by ATPLite Kits (PerkinElmer; Waltham, MA) performed according the manufacturer's instructions. Luminescence was read using a multi-scan plate reader (Fisher). For experiments utilizing etoposide-induced senescence, IMR90 human lung fibroblasts (passage 10; ATCC) were treated for 48 h with 20 μM etoposide (Enzo Life Sciences, Farmingdale, NY). Etoposide was removed and replaced with fresh media. Six days after etoposide removal, approximately 60% of IMR90 cells were SA-β-gal positive. Cells were treated for 48 h with 20 μM D+15 μM Q or 10 μM navitoclax (or untreated control) and the percentage of SA-β-gal-positive cells was determined using a C12FDG-based senescence assay described as follows46. Briefly, etoposide-treated senescent IMR90 cells were seeded at a concentration of 5 × 103 cells per well in 96-well plates 24 h before treatment. Following addition of the drugs, the cells were incubated for 48 h under 20% O2 oxygen conditions. For fluorescence analysis of SA-β-gal activity, cells were incubated for 1 h with 100 nM Bafilomycin A1 (Calbiochem, San Diego, CA). Next, 10 μM C12FDG (Setareh Biotech, Eugene, OR) was added to the culture medium and the cells were incubated for 1.5–2 h. Ten minutes before analysis, the DNA intercalating Hoechst dye (2 μg ml−1) was added to the cells. For quantitative analysis of cell number (Hoechst staining) and number of C12FDG-positive senescent cells, a laser-based line scanning confocal imager IN Cell 6000 Analyzer was used. All samples were analysed in duplicate with three to five fields per well.
What the sources say
- Partly supportedcites [32] Baker, D. J. et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 530, 184–189 (2016). sourceExperimental — accuracy not yet measured
In “ATTAC clears senescent adipocyte progenitor cells” (page unavailable), the paper identifies cells using p16 expression, other senescence markers, and SAβ-Gal staining. It studies naturally occurring senescent cells, however, and does not support the claim’s 21-day post-radiation condition. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Importantly, CM collected from irradiated bronchiolar epithelial cells did not activate a fibrogenic response, as measured by αSMA fibrotic activation of naive IMR90 cells (Supplementary Fig. 2), suggesting that cell-type-specific SASP composition may differentially affect pathological phenotypes within the lung.”
§ Cellular senescence mediates fibrotic pulmonary disease > Results > The secretome of senescent fibroblasts is profibrotic
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
61 more claims
Create a free account to see all 115 claims and to verify the 5 references still open.
- It may state two separate claims as one. 29
- Probably not a substantial claim. 26
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is in agreement with a recent report showing that the removal of senescent cells expressing high levels of p16INK4a can lead to fibrosis in mice101, whereas small-molecule senolytics appear to reduce fibrosis in several mouse tissues22,71,73,75,102.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in a mouse model of idiopathic pulmonary fibrosis (IPF), D + Q treatment improved lung compliance and reduced frailty71.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with IPF accumulate TAFs and senescence markers in lungs that increase with disease severity and activate SASP52.”
From Telomere dysfunction in ageing and age-related diseases (2022) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of various natural flavonoids, including quercetin and fisetin, either alone or in combination with dasatinib, a pan-tyrosine kinase inhibitor, can stimulate senolysis in a variety of contexts in vitro and in vivo199,207–210.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“consistent with enhanced paracrine signaling from increased numbers of senescent neighbors and with established features of epithelial aging.23,25,32–35”
From SenCat: Cataloging human cell senescence through multi-omic profiling of multiple senescent primary cell types (2026) · cites this paper as [33]
Experimental — accuracy not yet measured
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670
Self-citationNaturally occurring p16Ink4a-positive cells shorten healthy lifespan
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., et al. (2016) · Nature · doi:10.1038/nature16932 · Cited by 2,876 · cited 2×
“Attenuation of age-related pathologies and extension of lifespan in chronologically aged mice has been demonstrated using the same transgenic strategy 32–34 , and improvements in lung structure and function in aged mice have recently been demonstrated using a similar suicide-gene strategy 20 .”
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
The role of senescent cells in ageing
van Deursen, J. M. (2014) · Nature · doi:10.1038/nature13193 · Cited by 2,623
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,584 · cited 2×
“An alternative approach to transgenic senescent cell clearance is senolytics 21,22 , which may be a tractable treatment option for humans.”
Self-citationDesmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA
Demaria, M., Ohtani, N., Youssef, S. A., Rodier, F., Toussaint, W., Mitchell, J. R., Laberge, R.-M., Vijg, J., Van Steeg, H., Dollé, M. E. T., et al. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.11.012 · Cited by 2,045
Senescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
Cited by
Items 1,101–1,200 of 1,619
Li, J., Zhao, K., Yang, G., Lv, H., Zhang, R., Li, S., Chen, Z., Xu, M., Yang, N., & Dai, S. (2025) · Molecules · doi:10.3390/molecules30122653 · Cited by 5
Zhang, X., Zhao, W., Hu, X., Shen, Y., Gan, Y., Zou, J., Zhou, Y., Zhu, T., & Shen, T. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.118629 · Cited by 5
Cellular Senescence: A Pathogenic Driver for Pulmonary Fibrosis
Wang, S., Wang, R., He, Q.-Y., Ma, Y., Fang, Y., Yang, J., Zhao, H., Fu, L., & Chen, D. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl37811 · Cited by 5
HDAC11-Mediated Deacetylation of Triosephosphate Isomerase 1 Promotes Idiopathic Pulmonary Fibrosis
Li, Y., Shi, X., Zhang, F., Zhou, X., Zhu, X., Chen, J., Fu, K., Chen, J., Yang, J., Chen, Z., et al. (2025) · Research · doi:10.34133/research.0953 · Cited by 9
Han, L., Wang, C., Guo, X., Luo, Y., Zhang, J., He, F., Zeng, Z., Jiang, L., Ouyang, W., Gong, Y. Q., et al. (2025) · Advanced Science · doi:10.1002/advs.202509973 · Cited by 9
Decoding senescent drivers in Alzheimer's disease: From bench to bedside
Zhou, R., Lin, X., Liao, Z., Lin, J., Zheng, R., Ni, H., Liu, W., Feng, Z., He, Q., Lin, X., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102978 · Cited by 4
Stem Cell and Exosome Therapy in Wound Healing: Traps, Paradoxes, and Tricks Transforming Paradigms
Velikic, G. S., Šupić, G., Maric, D. L., Puletic, M., Maric, M. D., Barac, B., & Maric, D. M. (2025) · Biomedicines · doi:10.3390/biomedicines13123030 · Cited by 14
Senotoxins target senescence via lipid binding specificity, ion imbalance and lipidome remodeling
Moral‐Sanz, J., Fernández‐Carrasco, I., Ramponi, V., Garrido, A., Karbat, I., Cabezas‐Sainz, P., Rivera‐de‐Torre, E., Elsallabi, O., Martín-Hernández, R., López-Aceituno, J. L., et al. (2026) · Nature Aging · doi:10.1038/s43587-025-01030-w · Cited by 8
Self-citationSong, L., Yang, Y., Fu, Y., Liu, Y., Li, Q., Zheng, M., Yao, C., Song, D., Su, R., Chen, W., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106142 · Cited by 12
Fueling the fire: metabolic dysfunction and senescence as drivers of lung aging and disease
Kliment, C. R., Gurkar, A. U., Cárdenes, N., Ramonell, R. P., Finkel, T., & Königshoff, M. (2026) · Physiological Reviews · doi:10.1152/physrev.00024.2025 · Cited by 7
The aging extracellular matrix as a missing link in senescent cell accumulation and persistence
Bellido, N. H., Perramon‐Güell, A., & Anerillas, C. (2026) · Nature Aging · doi:10.1038/s43587-026-01127-w · Cited by 6
The Therapeutic Potential of CDK4/6 Inhibitors, Novel Cancer Drugs, in Kidney Diseases
Liang, X.-B., Dai, Z.-C., Zou, R., Tang, J., & Yao, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713558 · Cited by 5
Fan, J., Liu, X., & Guo, S. (2024) · Reproductive Sciences · doi:10.1007/s43032-024-01599-4 · Cited by 6
Zhou, S., Peng, L., Wang, Y., Cheng, D., Li, Z., Xiong, H., Wang, T., Liu, Y., Jia, Z., Sun, W., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156714 · Cited by 5
Kasperová, B. J., Cinkajzlová, A., Horváth, L., Svoboda, P., Haluzík, M., & Hubáčková, S. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1622107 · Cited by 5
Weng, S., Zuo, J., Mo, J., & Ye, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1557848 · Cited by 5
Novel Insight of Posterior Capsule Opacification: The Role of Lens Epithelial Cell Senescence
Ma, Y., Ren, Z., Chen, Y., Lu, Q., Ju, R., Qin, Y., & Wu, M. (2025) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.14582 · Cited by 4
Shi, M., Wang, W., Posum, W., Shi, J., Cui, H., Sun, Z., Chen, X., Chen, J., Wang, J., & Shi, X. (2025) · Aging Cell · doi:10.1111/acel.70174 · Cited by 4
Reversing coma by senolytics and stem cells: the future is now
Ichim, T. E., Ramos, R. A., Rath, A. V., Castellano, J., Azimi, N. A., Veltmeyer, J. D., Koumjian, M. P., Nicole, E. U., Bajnath, A., Lin, E. S., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07099-6 · Cited by 4
Leukocyte metabolism in obese type 2 diabetic individuals associated with COVID-19 severity
Lobato, T. B., Gennari-Felipe, M., Pauferro, J. R. B., Correa, I. S., Santos, B. F., Dias, B. B., Borges, J. C. D. O., dos Santos, C. S., Santos, E. S. D. S., de Araújo, M. J. L., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1037469 · Cited by 5
Palazzo, A., Makulyte, G., Goerhig, D., Médard, J., Gros, V., Trottein, F., Adnot, S., Vindrieux, D., Flaman, J., & Bernard, D. (2023) · Aging · doi:10.18632/aging.205259 · Cited by 4
Huang, J., Wang, X., Zeng, Y., Xu, H., Zhang, S., Ding, Z., & Guo, R. (2024) · Gene · doi:10.1016/j.gene.2024.148840 · Cited by 5
Dong, Z., Wang, X., Wang, P., Bai, M., Wang, T., Chu, Y., & Qin, Y. (2024) · Advanced Biology · doi:10.1002/adbi.202400297 · Cited by 6
Aging, brain-derived neurotrophic factor, and allergen-induced pulmonary responses in mice
Drake, L. Y., Roos, B. B., Wicher, S. A., Khalfaoui, L., Nesbitt, L. L., Fang, Y. H., Pabelick, C. M., & Prakash, Y. S. (2024) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00145.2024 · Cited by 4
Self-citationRegulation of the Cilia as a Potential Treatment for Senescence and Tumors: A Review
Zhu, D., Pan, Y., Yang, Y., & Wang, S. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31499 · Cited by 4
Jordan, M., Schmidt, K., Fuchs, M., Just, A., Pfanne, A., Willmer, L., Neubert, L., Werlein, C., Zardo, P., Pich, A., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1534989 · Cited by 6
GDF11-secreting cell transplant efficiently ameliorates age-related pulmonary fibrosis
Guo, L., Duchesneau, P., Jong, E. D., Sawula, E., Li, C., Waddell, T. K., & Nagy, A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.07.003 · Cited by 4
An RNA-seq primer for pulmonologists
Chu, S. G., Poli, S., Raby, B. A., & Rosas, I. O. (2019) · European Respiratory Journal · doi:10.1183/13993003.01625-2018 · Cited by 4
Targeting the nasty nestin to shoot lung fibrosis
Burgy, O., Crestani, B., & Bonniaud, P. (2022) · European Respiratory Journal · doi:10.1183/13993003.03146-2021 · Cited by 4
Therapeutic Potential of a Senolytic Approach in a Murine Model of Chronic GVHD
Raman, D., Chêne, C., Nicco, C., Jeljeli, M. M., Eu, J. Q., Clement, M., Batteux, F., & Pervaiz, S. (2023) · Biology · doi:10.3390/biology12050647 · Cited by 6
Cellular Senescence Program is Sensitive to Physical Differences in Polymeric Tissue Scaffolds
Yadav, P., Shah, R., Roy, A., Jani, S., Chatterjee, K., & Saini, D. K. (2023) · ACS Materials Au · doi:10.1021/acsmaterialsau.3c00057 · Cited by 5
Bonaroti, J. W., Ozel, M., Chen, T., Darby, J. L., Sun, X., Moheimani, H., Reitz, K. M., Kar, U. K., Zuckerbraun, B. S., Das, J., et al. (2023) · Journal of the American College of Surgeons · doi:10.1097/xcs.0000000000000922 · Cited by 5
Imaduddin, U., Berbudi, A., & Rohmawaty, E. (2024) · Journal of Experimental Pharmacology · doi:10.2147/jep.s439932 · Cited by 6
Almeida, M., & Manolagas, S. C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00012-9 · Cited by 6
Myofibroblast Functions in Tissue Repair and Fibrosis: An Introduction
Thannickal, V. J. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1382-5_2 · Cited by 6
Gene fusion of IL7 involved in the regulation of idiopathic pulmonary fibrosis
Sun, S., Huang, C., Leng, D., Chen, C., Zhang, T., Lei, K. C., & Zhang, X. D. (2021) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466621995045 · Cited by 4
Senescent cells and the dynamics of agingPreprint
Karin, O., Agrawal, A., Porat, Z., Krizhanovsky, V., & Alon, U. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/470500 · Cited by 4
Shee, S., Martinez-Martinez, Y. B., Koleske, B. N., Yabaji, S. M., Kobzik, L., Kramnik, I., & Bishai, W. R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.28.645957 · Cited by 4
Wang, P., Yang, M., Liu, W., & Chen, C. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114963 · Cited by 4
Identification of miR-106b-5p as a senolytic miRNA
Zhang, T., Nunes, A., O'Kelly, R. D., Angelini, L. A., Masternak, M. M., Suh, Y., Dong, X., Niedernhofer, L. J., & Robbins, P. D. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105810 · Cited by 3
Self-citationWang, Z.-N., Yang, X., Yu, Q., Xu, X., He, J., Zhong, N., & Tang, X. X. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167992 · Cited by 6
The emerging role of cellular senescence in amyotrophic lateral sclerosis
Tan, X., & Gao, N. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1599492 · Cited by 7
Transcription factor MEOX1 accelerates pulmonary fibrosis by regulating mitophagy and senescence
Fang, L., Lyu, L., Zhong, H., Lin, J., Ren, P., Wang, Y., Yin, Y., Zhang, M., & Qu, Y.-Q. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178043 · Cited by 4
A senescence-responsive nanodrug amplifies radiotherapy efficacy
Hua, Y., Song, H., Deng, H., Tian, H., Liu, C., Wu, H., Wang, S., Shao, C., Ye, L., Ge, S., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114202 · Cited by 3
Bousamaki, J., Rørbeck, E. A., Petersen, A. G., Korntner, S. H., Pors, S. E., Redente, E. F., Oró, D., Salinas, C. G., Olsen, R. W., Simonsen, U., et al. (2025) · Physiological Reports · doi:10.14814/phy2.70560 · Cited by 5
αCGRP deficiency aggravates pulmonary fibrosis by promoting senescence in alveolar type 2 cells
Lv, X., Chen, Q., Zhou, Z., Wu, W., Yu, X., & Zeng, Y. (2025) · Genes and Immunity · doi:10.1038/s41435-025-00361-3 · Cited by 3
Lee, J.-U., Nam, Y., Baek, J., Park, E. J., Hong, J., Choi, Y. M., Kim, S. H., Jeong, S. H., Kim, W. J., & Park, S. W. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.119146 · Cited by 6
Senescent fibroblasts modulate the radiation response of neighboring epithelial cells
Buchholzki, M., Stasch, L. M., Budeus, B., Ketheeswaranathan, V., Sevindik, Z. F., Jendrossek, V., & Klein, D. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02796-z · Cited by 6
Drosophila melanogaster : an old and future ally to radiobiology
Trinca, T. M., & de Navascués, J. (2025) · Journal of Radiation Research · doi:10.1093/jrr/rraf060 · Cited by 3
Epithelial AhR Suppresses Allergen-Induced Oxidative Stress and Senescence via c-Myc Regulation
Chen, Z., Gu, W., Wan, R., Zeng, Y., Xiang, X., Ouyang, R., & Gao, P. (2025) · Antioxidants · doi:10.3390/antiox15010022 · Cited by 6
Natural killer cell-based senotherapy: a promising strategy for healthy aging
中澤務, Yamanishi, R., Morimoto, T., & Matusda, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1737572 · Cited by 4
Li, T., Zhao, Q., Gao, Y., Zhang, Y., Song, Z., Huang, W., & Zhu, X. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.02.058 · Cited by 3
The Role of the Epidermal Growth Factor Receptor in Kidney Tubulointerstitial Fibrosis
Harris, R. C., & Zhang, M.-Z. (2026) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2026.151690 · Cited by 4
Zhu, S., Zhou, J. Q., Wang, K., Guo, M., & Sanders, Y. Y. (2026) · Aging · doi:10.18632/aging.206357 · Cited by 4
Dual-Functional PDA@Au/CeO 2 Nanozymes Enable CT Tracking and Potent Antifibrotic MSC Therapy
Guan, S., Yao, Y., Ding, Y., Zhang, L., Huangfu, J., Chen, X., Wang, X., & Zhou, J. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c18353 · Cited by 3
Immunological mechanisms and therapeutic approaches in pulmonary fibrosis
Nell, L. M., Hendriks, R. W., Wijsenbeek, M. S., Corneth, O. B. J., & Koudstaal, T. (2026) · European Respiratory Review · doi:10.1183/16000617.0227-2025 · Cited by 5
Qiao, Y., Zhao, J., Liu, M., Liu, J., Qiao, Z., Xu, R., Ning, X., Sun, S., & Chen, X. (2026) · Biomolecules · doi:10.3390/biom16040611 · Cited by 3
Natural killer cell immunotherapy reverses lung fibrosis by eliminating senescent fibroblasts
Merkt, W., Rodon, L., Deicher, F. S., Freitag, M., Claus, M., Lister, R. T., Han, H., Zhou, Y., Horne, A., Stütz, A. N., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adq5442 · Cited by 10
Zhavoronkov, A. A., Galkin, F., Chen, S., Ren, F., Aliper, A., Durymanov, M. O., Sidorenko, D., Cui, H., Han, J. J., Xu, H., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03286-y · Cited by 5
A precise dual-drug codelivery nanosystem for treating kidney failure by eliminating senescent cells
Jin, S., Li, W., Huang, Q., Zeng, X., & Zhang, X. (2024) · Science China Materials · doi:10.1007/s40843-024-2864-5 · Cited by 4
Alwanian, W. M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47030209 · Cited by 3
Targeted therapy for idiopathic pulmonary fibrosis: a bibliometric analysis of 2004–2024
Zhang, X., Yuan, Z., Shi, X., & Yang, J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1543571 · Cited by 3
Liu, J., Li, H., Sun, R., Ying, G., & Liang, Z. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03818-7 · Cited by 4
Wang, W., Chen, S., Xi, Z., Si, Y., Liu, Y., Chen, J., Wang, B., Zhu, D., & Gong, L. (2025) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0527oc · Cited by 4
Lithium carbonate induces myofibroblast necroptosis to reverse pulmonary fibrosis
Wei, K., Tang, L., Zhang, X., Liu, S., Tong, S., Bian, Y., Ma, Y., Zhu, T., Xiao, J., Lin, Q., et al. (2025) · Immunity & Inflammation · doi:10.1007/s44466-025-00002-4 · Cited by 3
The mapping of mRNA alterations elucidates the etiology of radiation-induced pulmonary fibrosis
Yuan, M., Zhao, M., Sun, X., & Hui, Z. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.999127 · Cited by 3
Standard of care drugs do not modulate activity of senescent primary human lung fibroblasts
Badaro‐Garcia, S., Hohmann, M. S., Coelho, A. L., Verri, W. A., Jr., & Hogaboam, C. M. (2023) · Scientific Reports · doi:10.1038/s41598-023-30844-0 · Cited by 4
Sánchez, Y. A., García, F. A., del Sol, D. O., Valdés‐Tresanco, M. E., Ortiz, C. D., Ramírez, B. S., & Alonso, I. P. (2023) · Physical Sciences Reviews · doi:10.1515/psr-2022-0288 · Cited by 4
Fang, H., Dong, T., Han, Z., Li, S., Liu, M., Liu, Y., Yang, Q., Fu, M., & Zhang, H. (2023) · International Journal of COPD · doi:10.2147/copd.s426763 · Cited by 6
Identification of cuproptosis-related diagnostic biomarkers in idiopathic pulmonary fibrosis
Wang, Q., Shang, Y., Li, Y., Li, X., Wang, X., He, Y., Ma, J., Ning, S., & Chen, H. (2024) · Medicine · doi:10.1097/md.0000000000036801 · Cited by 4
Wyles, S. P., Vyas, K. S., Wasserburg, J. R., Ansaf, R. B., & Kirkland, J. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15500-0.00009-8 · Cited by 4
Self-citationBao, Y., Yang, S., Zhao, H., Wang, Y., Li, K., Liu, X., Zhang, W., & Zhu, X. L. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-02976-0 · Cited by 4
Shanmugasundaram, M., Xu, S., Yang, Y., Huat, T. J., Lam, T. Y. W., & Ge, R. (2024) · hLife · doi:10.1016/j.hlife.2024.05.006 · Cited by 4
The Effects of Extracorporeal Shock Wave Therapy on Cutaneous Radiation Injury in a Mouse Model
Park, S. W., Shin, J., Jeong, B. K., Byun, S., Lee, K. S., & Choi, J. (2024) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000011782 · Cited by 4
Combating Cellular Aging: Frontiers in Biomaterials and Therapies
Liu, S., Mou, J., Zhao, C., Du, C., Liu, J., Bao, W., Xiao, H., Huang, W., Liao, J., & Lei, Y. (2024) · ACS Materials Letters · doi:10.1021/acsmaterialslett.4c02108 · Cited by 6
Gomez, L. S., & Jurk, D. (2024) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-66768-8_5 · Cited by 4
Investigational gene expression inhibitors for the treatment of idiopathic pulmonary fibrosis
Spagnolo, P., Tonelli, R., Mura, M., Reisman, W. M., Sotiropoulou, V., & Tzouvelekis, A. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2462592 · Cited by 3
Lin, F., Lin, K., Li, D., Kong, W., Zhuang, J., He, W., Wei, X., Xiao, T., Zu, H., Zhang, Z., et al. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03696-9 · Cited by 3
Normothermic Preservation of Liver – What Does the Future Hold?
Bral, M., & Shapiro, A. M. J. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_517 · Cited by 3
Huang, L., Shen, Y., Liu, C., Li, C., & Wang, J. (2020) · 南方医科大学学报 · doi:10.12122/j.issn.1673-4254.2020.12.13 · Cited by 4
A Small Molecule That Promotes Cellular Senescence Prevents Fibrogenesis and Tumorigenesis
Meang, M. K., Kim, S., Kim, I. H., Kim, H.-S., & Youn, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126852 · Cited by 4
Immunohistochemistry and Molecular Biology in Transbronchial Cryobiopsies
Chilosi, M., Marcolini, L., Caliò, A., & Poletti, V. E. (2019) · Springer eBooks · doi:10.1007/978-3-030-14891-1_9 · Cited by 3
Effect of anti‐interleukin‐17 biologics on Krebs von den Lungen‐6 level in patients with psoriasis
Hara, H., Miyagawa, H., Araya, J., Minagawa, S., Numata, T., Umezawa, Y., Asahina, A., Nakagawa, H., & Kuwano, K. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15895 · Cited by 4
A Geroscience Approach to Preventing Pathologic Consequences of COVID-19
Dou, Y., Fatemi, S., Darvas, M., Gale, M., & Ladiges, W. (2020) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2020.29018.dou · Cited by 4
[The effect of deep branches of cervical nerve on motorial function of trapezius muscle].
Wang, F., Wen, Y., & Li, L. (2003) · 华西口腔医学杂志 · Cited by 4
Cuevas-Mora, K., Roque, W., Sales, D., Ritzenthaler, J. D., Torres-González, E., Halayko, A. J., Rosas, I. O., Roman, J., & Romero, F. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.10.036327 · Cited by 3
Editorial: Telomere Dysfunction and Lung Diseases
Córdoba-Lanús, E., & Falfán‐Valencia, R. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.861228 · Cited by 3
Barkovskaya, A., Kim, K., Shankar, A., Meca-Laguna, G., Rae, M. J., Saux, C. J. L., & Sharma, A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.19.644224 · Cited by 3
Transcriptional factor RUNX1: A potential therapeutic target for fibrotic pulmonary disease
LIU, J., WANG, F., YUAN, B., & Luo, F. (2023) · Biocell · doi:10.32604/biocell.2023.026148 · Cited by 3
Kuhn, P. M., Chen, S., Venkatraman, A., Abadir, P. M., Walston, J. D., & Kokkoli, E. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.3c01461 · Cited by 3
Myeloid‐Mesenchymal Crosstalk in Lung Fibrosis
Bhattacharyya, A., Yadav, P., & Bhattacharya, M. (2025) · Comprehensive physiology · doi:10.1002/cph4.70004 · Cited by 3
Zhong, W., Xiong, J., Zhang, C., Jin, L., Yang, N., Sha, H.-X., Liu, Y., Duan, J., Guan, C., Zhou, Y., et al. (2025) · Histochemistry and Cell Biology · doi:10.1007/s00418-025-02374-5 · Cited by 4
Nojima, Y., & Mizuguchi, K. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108560 · Cited by 2
Emerging Concepts in Therapeutic Interventions for Idiopathic Pulmonary Fibrosis
Schott, C. A., Mohning, M. P., & Cooley, J. C. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2651-1937 · Cited by 7
Senolytic therapy increases replicative capacity by eliminating senescent endothelial cells
Abdeahad, H., Moreno, D. G., Bloom, S. I., Huang, H., Lesniewski, L. A., & Donato, A. J. (2025) · Experimental Gerontology · doi:10.1016/j.exger.2025.112885 · Cited by 3
Jha, R., Shi, J., Sedgwick, M. J., Sui, J., Corcoran, T. E., & Kliment, C. R. (2025) · Aging Cell · doi:10.1111/acel.70264 · Cited by 3
Parvanov, D. A., Ganeva, R., Ruseva, M., Handzhiyska, M., Safir, J., Jelezarsky, L., Vidolova, N., Metodiev, D., Stamenov, G., & Hadjidekova, S. P. (2025) · Diagnostics · doi:10.3390/diagnostics15212679 · Cited by 3
CCN1: a SASPy protein that plays multifaceted roles in fibrogenesis
Leask, A. (2025) · Matrix Biology · doi:10.1016/j.matbio.2025.11.007 · Cited by 6
Modulation of an aberrant basal cell program in human alveolar epithelial spheroids and lung slices
Li, Y., Wellmerling, J. H., Rosas, L., Link, P. A., Chow, D., Alvarez, J., Choi, K. M., Espinosa, A. M. D., Gilbert, R. M., Goplen, N., et al. (2025) · Respiratory Research · doi:10.1186/s12931-025-03441-0 · Cited by 4
Self-citationAging as a multifactorial disorder with two stages
Gems, D., Carver, A., & Zhao, Y. (2025) · Aging · doi:10.18632/aging.206339 · Cited by 3
Metadata
- Authors
- Schafer, M. J., White, T. A., Iijima, K., Haak, A. J., Ligresti, G., Atkinson, E. J., Oberg, A. L., Birch, J., Salmonowicz, H., Zhu, Y., Mazula, D. L., Brooks, R. W., Fuhrmann-Stroissnigg, H., Pirtskhalava, T., Prakash, Y. S., Tchkonia, T., Robbins, P. D., Aubry, M. C., Passos, J. F., Kirkland, J. L., Tschumperlin, D. J., Kita, H., & LeBrasseur, N. K.
- Affiliations
- Mayo Clinic (US)
- Newcastle University (GB)
- Scripps Research Institute (US)
- Corresponding author
- LeBrasseur, Nathan K.
- ORCID
- Venue
- Nature Communications
- Published
- 2017-02-23
- Volume
- 8
- Issue
- 1
- Pages
- 14532-14532
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5331226
- OpenAlex
- W2591114726
- Cited by
- 1,613
- References
- 52
- Citations by year
- 2026: 195 · 2025: 205 · 2024: 193 · 2023: 193 · 2022: 192 · 2021: 181 · 2020: 176 · 2019: 128 · 2018: 107 · 2017: 42
- FWCI
- 91.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- Mayo Clinic (UL1-TR000135)
- Glenn Foundation for Medical Research
- Louisiana Transportation Research Center
- Georgia Clinical and Translational Science Alliance (UL1 TR000135)
- Noaber Foundation
- Fondation pour la Recherche Médicale
- National Institutes of Health (UL1TR000135, 2r01hl092961-13)
- Directorate for Biological Sciences
- Biotechnology and Biological Sciences Research Council (BB/K017314/1, BB/H022384/1)
- National Institute on Aging (R01AG053832, R01AG013925, R37AG013925)
- National Heart, Lung, and Blood Institute (R01-HL-092961)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- cellular senescence, idiopathic pulmonary fibrosis, senolytics, senescence-associated secretory phenotype, senescent fibroblasts, p16, bleomycin-induced lung injury, interstitial pulmonary fibrosis, suicide gene therapy, lung function
- MeSH terms
- Animals, Bleomycin, Fibroblasts, Humans, Lung, Male, Biomarkers, Cellular Senescence, Cyclin-Dependent Kinase Inhibitor p16, Proteome, Mice, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.